{"title":"Salix以26亿美元收购Santarus，增加胃肠病学特许经营权","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I11.1992","DOIUrl":null,"url":null,"abstract":"Gastroenterology specialist Salix Pharmaceuticals has agreed to acquire Santarus in an all-cash transaction that values the company at approximately US$2.6 B. The acquisition will strengthen Salix’s commercial presence in gastroenterology, providing it with access to the primary care market and an ulcerative colitis drug with high growth potential. It will also provide diversification into new therapy areas, adding products such as Glumetza® (metformin extended-release) for type 2 diabetes and Fenoglide® (fenofibrate) for high cholesterol. The combined company will have estimated 2013 pro forma revenue of US$1.3 B from a portfolio of 22 marketed products.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"17 7","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2013-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Salix Adds to Gastroenterology Franchise with US$2.6 B Santarus Acquisition\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2013I11.1992\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Gastroenterology specialist Salix Pharmaceuticals has agreed to acquire Santarus in an all-cash transaction that values the company at approximately US$2.6 B. The acquisition will strengthen Salix’s commercial presence in gastroenterology, providing it with access to the primary care market and an ulcerative colitis drug with high growth potential. It will also provide diversification into new therapy areas, adding products such as Glumetza® (metformin extended-release) for type 2 diabetes and Fenoglide® (fenofibrate) for high cholesterol. The combined company will have estimated 2013 pro forma revenue of US$1.3 B from a portfolio of 22 marketed products.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"17 7\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-11-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2013I11.1992\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2013I11.1992","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Salix Adds to Gastroenterology Franchise with US$2.6 B Santarus Acquisition
Gastroenterology specialist Salix Pharmaceuticals has agreed to acquire Santarus in an all-cash transaction that values the company at approximately US$2.6 B. The acquisition will strengthen Salix’s commercial presence in gastroenterology, providing it with access to the primary care market and an ulcerative colitis drug with high growth potential. It will also provide diversification into new therapy areas, adding products such as Glumetza® (metformin extended-release) for type 2 diabetes and Fenoglide® (fenofibrate) for high cholesterol. The combined company will have estimated 2013 pro forma revenue of US$1.3 B from a portfolio of 22 marketed products.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
